Lersch C, Zeuner M, Bauer A, Siebenrock K, Hart R, Wagner F, Fink U, Dancygier H, Classen M
II. Department of Internal Medicine, Technical University of Munich, FRG.
Arch Geschwulstforsch. 1990;60(5):379-83.
Outpatients with inoperable far advanced hepato-cellular carcinomas (n = 5) were treated with LDCY--300 mg/m2 i.v. every 28 days-, echinacin--60 mg/m2 i.m.--and thymostimulin--30 mg/m2 i.m., day 3-10 after LDCY, then twice a week. Therapy was well tolerated by all patients. Their Karnofsky' index increased for 10% in the mean. A stable disease for more than 8 weeks was documented by abdominal ultrasonography in one patient. Serum levels of Alpha-Fetoprotein (AFP), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) did not increase in 2 patients. Median survival time was 2.5 months. One patient is still alive after 8 months. Absolute numbers of CD8+ cells significantly (p less than 0.02) decreased for 7% 1 day after LDCY, whereas CD4+ cells increased (p less than 0.02) from day 1-7. Numbers of natural killer (NK-) cells increased for 17% (p less than 0.05), their activity for 90% (p less than 0.05). Activities of peripheral polymorphs (p less than 0.05) increased for 27% and of Lymphokine Activated Killer (LAK-) cells for 180% (p less than 0.05).
5例无法手术的晚期肝细胞癌门诊患者接受了LDCY治疗（300mg/m²静脉注射，每28天一次）、棘霉素治疗（60mg/m²肌肉注射）和胸腺刺激素治疗（30mg/m²肌肉注射，在LDCY治疗后的第3 - 10天，然后每周两次）。所有患者对治疗耐受性良好。他们的卡氏评分平均提高了10%。腹部超声显示1例患者疾病稳定超过8周。2例患者的甲胎蛋白（AFP）、癌胚抗原（CEA）和组织多肽抗原（TPA）血清水平未升高。中位生存时间为2.5个月。1例患者8个月后仍存活。LDCY治疗1天后，CD8⁺细胞绝对数量显著减少7%（p＜0.02），而CD4⁺细胞从第1天到第7天增加（p＜0.02）。自然杀伤（NK）细胞数量增加17%（p＜0.05），其活性增加90%（p＜0.05）。外周多形核细胞活性增加27%（p＜0.05），淋巴因子激活杀伤（LAK）细胞活性增加180%（p＜0.05）。
